Tinzaparin

Heart Disease

Volumn 4, Issue 5, 2002, Pages 331-340

  Wong, Nina N ^a  

^a MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; DEXTRAN 70; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; WARFARIN;

BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; GENERAL SURGERY; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; LUNG EMBOLISM; ORTHOPEDIC SURGERY; REVIEW; THROMBOEMBOLISM; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

EID: 0036745118     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00132580-200209000-00009     Document Type: Review

References (58)

1. National Heart, Lung, Blood Institute. Morbidity and mortality chartbook on cardiovascular, lung, and blood diseases. Available at: http://www.nhlbi.nih.gov/resources/docs/00chtbk.pdf. Assessed May 2000;10:2002.
2. American College of Cardiology/American Heart Association. Task Force on Practice Guidelines (Committee on management of acute myocardial infarction). J Am Coll Cardiol 1996;28:1328-1428.
3. Centers for Disease Control and Prevention. MMWR 2002;51:126.
4. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: update. J Am Coll Cardiol 2001;2001:38:1581-1583.
5. Martineau P, Tawil N. Low molecular weight heparins in the treatment of deep vein thrombosis. Ann Pharmacother 1998;32:588-601.
6. Baker WF, Bick RL. Deep vein thrombosis: diagnosis and management. Med Clin North Am 1994;78:685-713.
7. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119:132S-175S.
8. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the ACS. New Engl J Med 1992;326:242-250.
9. Zed PJ, Tisdale JE, Borzak S. Low molecular weight heparins in the management of ACS. Arch Intern Med 1999;159:1849-1857.
10. Weitz JI, Bates S. Beyond heparin and aspirin. Arch Inter Med 2000;160:749-758.
11. Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet 2001;358:1533-1538.
12. Kleinschmidt K. Acute coronary syndrome: pharmacothcrapeutic interventions for unstable angina and non ST-T wave elevation myocardial infarction (NSTEMI). Clinical Concensus Reports 2002. Accessed at www.ahcpub.com/ach_root_html/ccr/acs_ptIII.html on June 20, 2002.
13. Hull RD, Pineo GF. Low molecular weight heparin in the treatment of venous thromboembolism. Semin Thromb Hemost 2000;26(Suppl 1):61-67.
14. Bergqvist D. Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolis and in ACS. Pharmacoeconomics 2002;20:225-243.
15. Marchetti M, Pistorio A, Barone M, et al. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Mod 2001;111:130-139.
16. Bell GK, Goldhaber SZ. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement. Vasc Med 2001;6:23-29.
17. Nader HB, Walenga JM, Berkowitz SD, et al. Preclinical differentiation of low molecular weight heparins. Semin Thromb Hemost 1999;25:63-72.
18. Planès A, Vochelle N, Fafola M. Venous thromboembolic prophylaxis in orthopedic surgery: knee surgery. Semin Thromb Hemost 1999;25:73-82.
19. Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 2000;26(Suppl 1):5-21.
20. Cziraky MJ, Spinier SA. Low molecular weight heparins for the treatment of deep vein thrombosis. Clin Pharm 1993;12:892-899.
21. Mammen EF, Arcelis J, Messmore H. Clinical differentiation of low molecular weight heparins. Semin Thromb Hemost 1999;25(Suppl 3):135-144.
22. Friedel HA, Balfour JA. Tinzaparin: a review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 1994;48:638-660.
23. Lopez LM. Low molecular weight heparins are essentially the same for treatment and prevention of venous thromboembolism. Pharmacotherapy 2001;21(6 Pt 2):565-615.
24. Tinzaparin (Innohep) package insert. Ballerup, Denmark: Leo Pharmaceutical Products, 2000.
25. Hedner U. Development of tinzaparin: a heparinase-digested low molecular weight heparin. Semin Thromb Hemost 2000;26(Suppl 1):23-29.
26. Matzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymatically depoly-merized heparin as compared with conventional heparin in healthy volunteers. Thromb Haemost 1987;57:97-101.
27. Siguret V, Pautas E, Fevrier M, et al. Elderly patient treated with tinzaparin administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over ten days. Thromb Haemost 2000;84:800-804.
28. Cornelli U, Fareed J. Human pharmacokinetics of low molecular weight heparins. Semin Thromb Hemost 1999;25:57-61.
29. Davidson BL. Differentiation of low molecular, weight heparins in treatment of acute deep vein thrombosis. Semin Thromb Hemost 1999;25:107-112.
30. Eriksson BI, Soderberg K, Widlund L, et al. A comparative study of three low molecular weight heparins and unfractionated heparin in healthy volunteers. Thromb Hemost 1995;73:398-401.
31. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-193S.
32. Cairns JA, Theroux P, Lewis LID, et al. Antithrombotic agents in coronary artery disease. Chest 2001;119:2285-2525.
33. Duplaga B, Rivers C, Nutescu E. Dosing and monitoring of low molecular weight heparins in special populations. Pharmacotherapy 2001;21:218-234.
34. Breddin HK. Low molecular weight heparins in the prevention of deep vein thrombosis in general surgery. Semin Thromb Hemost 1999;25:83-89.
35. Breddin HK. Prophylaxis and treatment of deep vein thrombosis. Sem Thromb Hemost 2000;26:47-52.
36. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low molecular weight heparin with warfarin sodium for prophylaxis against deep vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-1376.
37. Planès A, Samama MM, Lensing AWA, et al. Prevention of deep vein thrombosis after hip replacement-comparison between two low molecular weight heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;81:22-25.
38. Planès A. An equivalence study of two low molecular weight heparins in the prevention and treatment of deep vein thrombosis after total hip replacement. Semin Thromb Hemost 2000;26:57-60.
39. Lassen MR, Borris LC, Jensen HP, et al. Dose relation in the prevention of proximal vein thrombosis with a lowmolecular weight heparin (tinzaparin) in elective hip arthroplasty. Clin Appl Thromb Hemost 2000;6:53-57.
40. Green D. Prevention of thromboembolism after spinal cord injury. Semin Thromb Hemost 1991;17:347-350.
41. Hong-Dice YG, Papini JR, Ornstein DL. Low molecular weight heparins for the prevention and treatment of venous thromboembolism. Mil Med 2001;166:593-601.
42. Gould M, Dembitzer A, Doyle R, et al. Low molecular weight heparins compared with unfractionated heparin for treatment of acute deep venous thromboembosis: a meta analysis of randomized, controlled trials. Ann Intern Med 1999;130:800-809.
43. Dolovich L, Ginsberg J, Douketis J, et al. A meta analysis comparing low molecular weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188.
44. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal vein thrombosis. N Engl J Med 1992;326:975-982.
45. Simmonneau G, Sors H, Carbonnier B, et al. Cornelli U, Fareed J. Human pharmacokinetics of low molecular weight heparins. Semin Thromb Hemost 1999;25:57-61.
46. Hull RD, Raskob GE, Brant RF, et al for the American-Canadian Thrombosis Study Group. Low molecular weight heparin versus heparin in the treatment of patients with pulmonary embolism. Arch Intern Med 2000;160:229-236.
47. Suvarna TT, Parikh JA, Keshav R, et al. Comparison of clinical outcome of fixed dose subcutaneous low molecular weight heparin (tinzaparin) with conventional heparin in UA: a pilot study. Indian Heart J 1997;49:159-162.
48. Michalis LK, Papamichail N, Katsouras CS, et al. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET study) (abstract). J Am Coll Cardiol 2001;37(2 Suppl A):365A.
49. Bath PMW, Lindenstrom E, Boysen G, et al for the TAIST investigators. Tinzaprin in Acute Ischemic Stroke (TAIST), a randomized aspirin-controlled trial. Lancet 2001;358:702-710.
50. Zacharski LR, Ornstein DL, Mamourian AC. Low molecular weight heparin and cancer. Semin Thromb Hemost 2000;26:69-77.
51. McEvoy GK, ed. American Hospital Formulary Service Drug Information 2002. Bethesda, D: American Society of Health Systems Pharmacist, 2002.
52. Simpson HKL, Baird J, Allison M, et al. Long term use of the low molecular weight heparin tinzaparin in hemodialysis. Hemostasis 1996;26:90-97.
53. Egfjord M, Rosenlund L, Hedegaard B, et al. Dose titration study of tinzaparin, a low-molecular weight heparin, in patients on chronic hemodialysis. Artif Organs 1998;22:633-637.
54. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWH. Semin Thromb Hemost 2000;26(Suppl 1):31-38.
55. Holst J, Lindblad B, Bergqvist D, et al. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man. Thromb Res 1997;86:343-348.
56. Weitz JI. Low molecular weight heparins. N Engl J Med 1997;337:688-698.
57. Lassen MR, Backs S, Borris LC, et al. Deep vein thrombosis prophylaxis in orthopedic surgery: hip surgery. Semin Thromb Hemost 1999;25:79-82.
58. Hull R, Raskob G, Rosenbloom D, et al. Treatment of proximal vein thrombosis with subcutaneous low molecular weight heparin versus intravenous heparin: an economic perspective. Arch Intern Med 1997;157:289-294.